UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 24, 2002
BIOENVISION, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-24875 13-4025857
(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)
Incorporation)
One Rockefeller Plaza, Suite 1600, New York, New York 10020
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (212) 445-6582
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
The Registrant is filing the attached material contracts as exhibits.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) and (b) Not Applicable
(c) Exhibit. The following exhibits are filed with this
report:
10.22 Exclusive License Agreement by and between Baxter
Healthcare Corporation, acting through its Edwards
Critical-Care Division, and Implemed, dated as of
May 6, 1997
10.23 License Agreement by and between Oklahoma Medical
Research Foundation and Bridge Therapeutic Products,
Inc., dated as of January 1, 1998
10.23(a) Amendment No. 1 to License Agreement by and among
Oklahoma Medical Research Foundation, Bioenvision,
Inc. and Pathagon, Inc., dated May 7, 2002
10.24 Inter-Institutional Agreement between Sloan-Kettering
Institute for Cancer Research and Southern Research
Institute, dated as of August 31, 1998
10.25 License Agreement between University College London
and Bioenvision, Inc., dated March 1, 1999
10.26 Research Agreement between Stegram Pharmaceuticals
Ltd., Queen Mary and Westfield College and
Bioenvision, Inc., dated June 8, 1999
10.27 Research and License Agreement between Bioenvision,
Inc., Velindre NHS Trust and University College
Cardiff Consultants, dated as of January 9, 2001
10.28 Co-Development Agreement between Bioenvision, Inc.
and Ilex Oncology, Inc., dated March 9, 2001
[Signature on following page.]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIOENVISION, INC.
By: /s/ Christopher B. Wood
----------------------------
Christopher B. Wood
Chief Executive Officer
Date: June 21, 2002
EXHIBIT INDEX
Exhibit Description
10.22 Exclusive License Agreement by and between Baxter Healthcare
Corporation, acting through its Edwards Critical-Care
Division, and Implemed, dated as of May 6, 1997
10.23 License Agreement by and between Oklahoma Medical Research
Foundation and Bridge Therapeutic Products, Inc., dated as of
January 1, 1998
10.23(a) Amendment No. 1 to License Agreement by and among Oklahoma
Medical Research Foundation, Bioenvision, Inc. and Pathagon,
Inc., dated May 7, 2002
10.24 Inter-Institutional Agreement between Sloan-Kettering
Institute for Cancer Research and Southern Research Institute,
dated as of August 31, 1998
10.25 License Agreement between University College London and
Bioenvision, Inc., dated March 1, 1999
10.26 Research Agreement between Stegram Pharmaceuticals Ltd., Queen
Mary and Westfield College and Bioenvision, Inc., dated
June 8, 1999
10.27 Research and License Agreement between Bioenvision, Inc.,
Velindre NHS Trust and University College Cardiff Consultants,
dated as of January 9, 2001
10.28 Co-Development Agreement between Bioenvision, Inc. ad Ilex
Oncology, Inc., dated March 9, 2001